Supplementary figure 3 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma | Synapse
October 2, 2025
Supplementary figure 3 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Key Points
Nrf2 hyperactivation contributes to resistance against radiotherapy, limiting treatment success.
The study highlights that the influence of Keap1 status and tobacco carcinogens complicates tumor response.
Observational analysis reveals a relationship between nrf2 activation and suppressed antitumor immune responses.
Understanding these mechanisms may enable the development of more effective therapeutic strategies.
Abstract
Primary tumor growth influenced by Keap1 status and tobacco carcinogen, BAP